India Ministry Renews Push For CL Of BMS Leukemia Drug
This article was originally published in PharmAsia News
Executive Summary
India's health ministry has made another push for a compulsory license of Bristol-Myer Squibb's Sprycel (dasatinib) for treating leukemia.